Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives

Sabrina Zulfikar, Sarah Mulholland, Huzaifa Adamali, Shaney L Barratt Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UKCorrespondence: Shaney L BarrattConsultant Respiratory Physician and Honorary Associate Researcher, North Bristol NHS Trust, Southmead Hospital, Southm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zulfikar S, Mulholland S, Adamali H, Barratt SL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	autotaxin inhibitors autotaxin-lysophosphatidic acid axis idiopathic pulmonary fibrosis interstitial lung disease fibrotic lung disease Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4d1c78ca5bdc493db7ac55a1f103b686
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d1c78ca5bdc493db7ac55a1f103b686
record_format	dspace
spelling	oai:doaj.org-article:4d1c78ca5bdc493db7ac55a1f103b6862021-12-02T12:13:09ZInhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives1179-1438https://doaj.org/article/4d1c78ca5bdc493db7ac55a1f103b6862020-07-01T00:00:00Zhttps://www.dovepress.com/inhibitors-of-the-autotaxin-lysophosphatidic-acid-axis-and-their-poten-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Sabrina Zulfikar, Sarah Mulholland, Huzaifa Adamali, Shaney L Barratt Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UKCorrespondence: Shaney L BarrattConsultant Respiratory Physician and Honorary Associate Researcher, North Bristol NHS Trust, Southmead Hospital, Southmead, Bristol BS10 5NB, UKEmail Shaney.Barratt@nbt.nhs.ukAbstract: Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.Keywords: autotaxin inhibitors, autotaxin-lysophosphatidic acid axis, idiopathic pulmonary fibrosis, interstitial lung disease, fibrotic lung diseaseZulfikar SMulholland SAdamali HBarratt SLDove Medical Pressarticleautotaxin inhibitorsautotaxin-lysophosphatidic acid axisidiopathic pulmonary fibrosisinterstitial lung diseasefibrotic lung diseaseTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 97-108 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	autotaxin inhibitors autotaxin-lysophosphatidic acid axis idiopathic pulmonary fibrosis interstitial lung disease fibrotic lung disease Therapeutics. Pharmacology RM1-950
spellingShingle	autotaxin inhibitors autotaxin-lysophosphatidic acid axis idiopathic pulmonary fibrosis interstitial lung disease fibrotic lung disease Therapeutics. Pharmacology RM1-950 Zulfikar S Mulholland S Adamali H Barratt SL Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
description	Sabrina Zulfikar, Sarah Mulholland, Huzaifa Adamali, Shaney L Barratt Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UKCorrespondence: Shaney L BarrattConsultant Respiratory Physician and Honorary Associate Researcher, North Bristol NHS Trust, Southmead Hospital, Southmead, Bristol BS10 5NB, UKEmail Shaney.Barratt@nbt.nhs.ukAbstract: Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.Keywords: autotaxin inhibitors, autotaxin-lysophosphatidic acid axis, idiopathic pulmonary fibrosis, interstitial lung disease, fibrotic lung disease
format	article
author	Zulfikar S Mulholland S Adamali H Barratt SL
author_facet	Zulfikar S Mulholland S Adamali H Barratt SL
author_sort	Zulfikar S
title	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_short	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_full	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_fullStr	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_full_unstemmed	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
title_sort	inhibitors of the autotaxin-lysophosphatidic acid axis and their potential in the treatment of interstitial lung disease: current perspectives
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/4d1c78ca5bdc493db7ac55a1f103b686
work_keys_str_mv	AT zulfikars inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives AT mulhollands inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives AT adamalih inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives AT barrattsl inhibitorsoftheautotaxinlysophosphatidicacidaxisandtheirpotentialinthetreatmentofinterstitiallungdiseasecurrentperspectives
_version_	1718394572029034496

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives

Ejemplares similares